骨质疏松症(OP)是一种以骨量减少、骨组织微结构损坏致骨脆性增加、易发生骨折为特征的全身性疾病,目前主要依靠药物治疗。由于OP和一些眼部疾病的发生均与衰老导致的一系列病理机制有关,并且OP治疗药物也具有抗非感染性炎症、抗氧化、抗凋亡、影响性激素水平等作用,与一些眼科疾病的发生机制存在一定的关联,从而对眼部疾病的发生和进展产生影响。OP治疗药物主要包括维生素D及其衍生物、雌激素、双膦酸盐、地舒单抗,这些药物的应用可能增加年龄相关性黄斑变性、干眼、眼部炎症的患病风险,也有可能对一些眼部疾病如干眼、白内障、青光眼、脉络膜新生血管等起到预防作用。故临床上使用OP治疗药物时,应定期观察相关眼病的变化。本文对OP治疗药物应用对眼部疾病的影响研究进行综述。
Osteoporosis (OP) is a systemic disease characterized by decreased bone mass, increased bone fragility due to damage to the microstructure of bone tissue, and susceptibility to fractures.At present, it mainly relies on pharmacologic treatment.Because the occurrence of OP and some eye diseases are associated with a series of age-related pathological mechanisms, and OP therapeutic drugs also have anti-non-infectious inflammation, antioxidant, anti-apoptosis, and sex hormone-regulating effects, there is a certain correlation with the pathogenesis of some ophthalmic diseases, and thus affect the onset and progression of eye diseases.The application of OP therapeutic drugs such as vitamin D and its derivatives, estrogen, bisphosphonates, and desuximab may increase the risk of age-related macular degeneration, dry eye, and ocular inflammation, and may also play a preventive role in some eye diseases such as dry eye, cataract, glaucoma, and choroidal neovascularization.Therefore, when OP therapeutic drugs are used clinically, the changes of related eye diseases should be regularly monitored.This article reviews the research on the effects of OP therapeutic drugs on eye diseases.
刘海钰,李甦雁. 骨质疏松症治疗药物应用对眼部疾病影响的研究进展[J]. 中华实验眼科杂志,2024,42(05):491-496.
DOI:10.3760/cma.j.cn115989-20230127-00028版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。
除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。